Mark S Pasternack

US Patent:

47834102, Nov 8, 1988

Filed:

Jun 28, 1985

Appl. No.:

6/750323

Inventors:

Mark S. Pasternack - Boston MA
Herman N. Eisen - Waban MA

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C12N 916
C12N 948
C12N 976

US Classification:

435196

Abstract:

A novel serine esterase produced by cytotoxic T lymphocytes is insolated and characterized. The protein appears to be membrane bound and has a reduced apparent molecular weight of about 28,000 daltons. Inhibition of the esterase correlates with inhibition of the cells' cytolytic activity. The serine esterase is useful in making antibody and as a target for the inhibition of cytolytic activity by T-lymphocytes, both in vivo and in vitro.

US Patent:

50174894, May 21, 1991

Filed:

Aug 22, 1988

Appl. No.:

7/234906

Inventors:

Mark S. Pasternack - Brookline MA
Herman S. Eisen - Waban MA

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

C12N 916
C12N 948
A61K 39395
A61K 3944

US Classification:

435196

Abstract:

Antibodies, nucleic acid sequences, and methods for inhibition of lysis for a novel serine esterase produced by both murine and human cytotoxic T lymphocytes. The serine esterase has an apparent molecular weight of approximately 28,000-31,000, as determined by SDS gel electrophoresis under reducing conditions, and trypsin-like activity. Inhibition of the esterase correlates with inhibition of the cells' cytolytic activity. Specific inhibition of the serine esterase is useful as a method for immunosuppression as well as for the inhibition of cytolytic activity of T lymphocytes, both in vivo and in vitro. The genes encoding the murine and human serine esterase are homologous.